Login to Your Account



AiCuris' Phase II CMV Drug Lures Merck: $142M Up Front

By Randy Osborne
Staff Writer

Wednesday, October 17, 2012
Merck & Co. Inc.'s tie of the licensing knot with AiCuris GmbH & Co. brought €110 million (US$142.2 million) up front and could mean another €332.5 million in milestone payments for AiCuris, with a cytomegalovirus (CMV) candidate impressive in Phase II trials.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription